Results 11 to 20 of about 9,294,018 (384)

Limited Substrate Specificity of PS/γ-Secretase Is Supported by Novel Multiplexed FRET Analysis in Live Cells

open access: yesBiosensors, 2021
Presenilin (PS)/γ-secretase is an aspartyl protease that processes a wide range of transmembrane proteins such as the amyloid precursor protein (APP) and Notch1, playing essential roles in normal biological events and diseases.
Mei C. Q. Houser   +5 more
doaj   +1 more source

New insights into the genetic etiology of Alzheimer’s disease and related dementias

open access: yesNature Genetics, 2022
Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes.
C. Bellenguez   +402 more
semanticscholar   +1 more source

Prescribing cholinesterase inhibitors in mild cognitive impairment—Observations from the Alzheimer's Disease Neuroimaging Initiative

open access: yesAlzheimer’s & Dementia: Translational Research & Clinical Interventions, 2021
Introduction Analyses of off‐label use of acetylcholinesterase inhibitors (AChEIs) in mild cognitive impairment (MCI) has produced mixed results. Post hoc analyses of observational cohorts, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI ...
Eddie Stage   +8 more
doaj   +1 more source

Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future

open access: yesSignal Transduction and Targeted Therapy, 2023
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer’s disease (AD), and its accumulation has been considered as the molecular driver of Alzheimer’s pathogenesis and progression.
Yun Zhang   +4 more
semanticscholar   +1 more source

A potential biomarker of cognitive impairment: The olfactory dysfunction and its genes expression

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1884-1897, December 2022., 2022
Abstract Objective Accumulation evidence has reported that olfactory impairment may be an essential clinical marker and predictor of mild cognitive impairment or Alzheimer's disease. Method Participants were enrolled in the population‐based, prospective study in Fuxin county, Liaoning province, China between 2019 and 2021.
Jiayi Song   +11 more
wiley   +1 more source

Mechanism and therapeutic potential of targeting cGAS-STING signaling in neurological disorders

open access: yesMolecular Neurodegeneration, 2023
DNA sensing is a pivotal component of the innate immune system that is responsible for detecting mislocalized DNA and triggering downstream inflammatory pathways.
Yige Huang   +4 more
doaj   +1 more source

Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE® system

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1898-1909, December 2022., 2022
Abstract Objectives Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated immunoassay platform, and brain β‐amyloid (Aβ ...
Hisashi Nojima   +9 more
wiley   +1 more source

Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease

open access: yesAlzheimer’s Research & Therapy, 2021
Background Comprehensive testing of cognitive functioning is standard practice in studies of Alzheimer disease (AD). Short-form tests like the Montreal Cognitive Assessment (MoCA) use a “sampling” of measures, administering key items in a shortened ...
Jason Hassenstab   +7 more
doaj   +1 more source

The Importance of Advancing Research on Aging and Driving

open access: yesGeriatrics, 2021
Between 2009 and 2018, the number of older adults (i [...]
Samantha A. Murphy   +2 more
doaj   +1 more source

Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1926-1940, December 2022., 2022
Abstract Objective Endothelial dysfunction is an early and prevalent pathology in Alzheimer disease (AD). We here investigate the value of vascular endothelial‐cadherin (VEC) as a cerebrospinal fluid (CSF) marker of endothelial injury in preclinical AD.
Rawan Tarawneh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy